BlackRock Group’s Alaunos Therapeutics TCRT Stock Holding History

BlackRock Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$448K	Buy	558 +33	+6%	+$29.7K	﹤0.01%	2399
2016 Q3	$444K	Buy	525 +14	+3%	+$11.3K	﹤0.01%	2349
2016 Q2	$422K	Buy	511 +13	+3%	+$14.2K	﹤0.01%	2328
2016 Q1	$554K	Buy	498 +163	+49%	+$167K	﹤0.01%	2200
2015 Q4	$418K	Buy	335 +167	+99%	+$276K	﹤0.01%	2270
2015 Q3	$227K	Buy	168 +49	+41%	+$80.9K	﹤0.01%	2496
2015 Q2	$214K	Buy	119 +40	+51%	+$62.1K	﹤0.01%	2559
2015 Q1	$128K	Buy	+79	New	+$117K	﹤0.01%	2604
2014 Q4	–	Sell	-30	Closed	-$12K	–	2911
2014 Q3	$12K	Buy	+30	New	+$14.5K	﹤0.01%	2792

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Group's TCRT Position: Q4 2016 in Review

BlackRock Group increased its Alaunos Therapeutics (TCRT) stake by 6.3% in Q4 2016, buying an estimated $29.7K and bringing the position to 558 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

BlackRock Group first reported a position in TCRT in Q3 2014 and has held it in 9 quarters since. The position peaked at $554K in Q1 2016. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

BlackRock Group held 558 shares of Alaunos Therapeutics worth $448K as of Q4 2016.
BlackRock Group bought 33 Alaunos Therapeutics shares in Q4 2016, an estimated $29.7K.
Alaunos Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2399 holding.
BlackRock Group first reported a position in Alaunos Therapeutics in Q3 2014 and has held it in 9 quarters since.
BlackRock Group's Alaunos Therapeutics position peaked at $554K in Q1 2016.
136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.